ArticleBMC complementary and alternative medicine2017
Flavonolignans inhibit the arachidonic acid pathway in blood platelets.
Article in BMC complementary and alternative medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- A review of natural compounds to regulate platelet aggregation: molecular mechanism and research advance.Frontiers in pharmacology · 2025Review
- Review
- Functional Foods in Preventing Human Blood Platelet Hyperactivity-Mediated Diseases-An Updated Review.Nutrients · 2024Review
- Metabolic profiling of milk thistle different organs using UPLC-TQD-MS/MS coupled to multivariate analysis in relation to their selective antiviral potential.BMC complementary medicine and therapies · 2024Article
- The combination of paeonol, diosmetin-7-Frontiers in pharmacology · 2024Article
- Antithrombotic and antiplatelet effects of plant-derived compounds: a great utility potential for primary, secondary, and tertiary care in the framework of 3P medicine.The EPMA journal · 2022Review
- Stimulating the Hematopoietic Effect of Simulated Digestive Product of Fucoidan fromMarine drugs · 2022Article
- Chitosan Elicitation Impacts Flavonolignan Biosynthesis inMolecules (Basel, Switzerland) · 2021Article
- Polyphenols: Modulators of Platelet Function and Platelet Microparticle Generation?International journal of molecular sciences · 2019Review
- The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo.Nutrients · 2019Article
- Roles of Phenolic Compounds in the Reduction of Risk Factors of Cardiovascular Diseases.Molecules (Basel, Switzerland) · 2019Review
- Inhibitory Effect of Flavonolignans on the P2Y12 Pathway in Blood Platelets.Molecules (Basel, Switzerland) · 2018Article
- Effect of Polyphenols FromFrontiers in pharmacology · 2018Article
- Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.Nutrients · 2017Article
- Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.Molecules (Basel, Switzerland) · 2017Review
- Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes.Nutrients · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArachidonic acid metabolism by cyclooxygenase (COX) is a major pathway for blood platelets' activation, which is associated with pro-thrombotic platelet activity and the production of pro-inflammatory mediators. Inhibition of COX activity is one of the major means of anti-platelet pharmacotherapy preventing arterial thrombosis and reducing the incidence of cardiovascular events. Recent studies have presented that a silymarin (standardized extract of Milk thistle (Silybum marianum)) can inhibit the COX pathway. Accordingly, the aim of our study was to determine the effects of three major flavonolignans (silybin, silychristin and silydianin) on COX pathway activity in blood platelets.
methodsWe determined the effect of flavonolignans on arachidonic acid induced blood platelet aggregation, COX pathway metabolites formation, as well as COX activity in platelets. Additionally, we analysed the potential mechanism of this interaction using the bioinformatic ligand docking method.
resultsWe observed that tested compounds decrease the platelet aggregation level, both thromboxane A
conclusionsThe results obtained from this study clearly present the potential of flavonolignans as novel antiplatelet and anti-inflammatory agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.